Seoulin Bioscience Co.,Ltd. (KOSDAQ:038070)
South Korea flag South Korea · Delayed Price · Currency is KRW
4,230.00
-265.00 (-5.90%)
At close: Aug 21, 2026

Seoulin Bioscience Revenue

Seoulin Bioscience had revenue of 19.53B KRW in the quarter ending March 31, 2026, with 8.28% growth. This brings the company's revenue in the last twelve months to 78.58B, up 5.38% year-over-year. In the year 2025, Seoulin Bioscience had annual revenue of 77.09B with 2.23% growth.

Revenue (ttm)
78.58B
Revenue Growth
+5.38%
P/S Ratio
0.46
Revenue / Employee
799.67M
Employees
104
Market Cap
38.20B

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 202577.09B1.68B2.23%
Dec 31, 202475.41B-14.16B-15.81%
Dec 31, 202389.57B-15.14B-14.46%
Dec 31, 2022104.71B24.17B30.01%
Dec 31, 202180.54B15.45B23.74%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
GC Medical Science105.48B
Dx & Vx28.48B
Cytogen27.38B
Protia17.75B
HLB Panagene14.64B
3billion11.71B
GENINUS10.24B
Median Diagnostics7.86B
Revenue Rankings